GlassScriptPhysician profile
Lorraine Cresanto
NPI 1487770962
$7,042.45
in general payments reported to CMS, 2019-2025
26 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,283 · 2022: $982 · 2023: $1,415 · 2024: $1,558 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,762 · Education: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,761.54 |
| Education | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,190.59 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $648.74 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $579.07 | 2021-2025 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $548.74 | 2021-2022 | |
| Qol Medical, LLC | $344.65 | 2021-2024 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $264.94 | 2024-2025 | Vowst, Zenpep |
| Gilead Sciences, INC. | $220.84 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $218.35 | 2021-2025 | Linzess |
| Nestle Healthcare Nutrition INC. | $176.65 | 2021-2023 | |
| Celltrion USA INC. | $135.24 | 2024-2025 | Vegzelma, Zymfentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.29 | 2023-2024 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $77.70 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $72.13 | 2021-2024 | Rebyota |
| Ardelyx, INC. | $67.87 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $64.04 | 2025 | Omvoh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $54.72 | 2025 | Rezdiffra |
| Genzyme Corporation | $44.50 | 2023 | |
| Novo Nordisk INC | $33.45 | 2025 | Wegovy |
| Celgene Corporation | $29.09 | 2022 | |
| Pfizer INC. | $25.62 | 2024 | |
| Biocon Biologics INC | $23.35 | 2025 | Yesintek |
| Merck Sharp & Dohme LLC | $21.72 | 2022 | |
| Intercept Pharmaceuticals, INC. | $18.76 | 2024 | |
| Amgen INC. | $17.91 | 2025 | Uplizna |
| Ipsen Biopharmaceuticals, INC | $15.17 | 2023 | Bylvay |
| Alfasigma USA, INC. | $14.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorraine Cresanto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.